Skip to content

The lowering effect of ezetimibe on serum lipids and serum lipoprotein in postprandial hyperlipidemi

The lowering effect of ezetimibe on serum lipids and serum lipoprotein in postprandial hyperlipidemi - The lowering effect of ezetimibe on serum lipids and serum lipoprotein in postprandial hyperlipidemi

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013611
Enrollment
35
Registered
2014-04-02
Start date
2014-03-08
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus with hyperlipidemia

Interventions

Sponsors

Nakakinen clinic
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1)Type 1 or secondary diabetes mellitus 2)With strong statin 3)With insulin 4)With Severe ketosis, diabetic coma or precoma 5)With any of myocardial infarction, angina pectoris, intracranial hemorrhage or cerebral infarction within 6 months 6)With moderate renal dysfunction(Serum CRE male:<1.4mg/dL, female:<1.2mg/dL) 7)With heart failure(HF) or history of HF 8)With severe hepatic dysfunction 9)With severe infection, perioperative period or severe injury 10)Patient who is pregnant, in lactation or suspected to be pregnant 11)Judged to be inadequate for including this study by PI or collaborators.

Design outcomes

Primary

MeasureTime frame
The value of RLP-C 4 hour after fat loading test

Secondary

MeasureTime frame
Value of serum lipid and AUC after fat loading test A value of blood glucose and AUC after fat loading test Changes in serum lipid during study period Changes in glycometabolism during study period Side effect

Countries

Japan

Contacts

Public ContactKensuke Ofuchi

Nakakinen clinic Clinical Laboratory

k-ofuchi@kensei-kai.com029-353-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026